The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa

Table 4

Characteristics of patients failing treatment-free remission.

Parameter		Overall	Patient 1	Patient 2	Patient 3
TFR failure, n (%)		3 (25)	—	—	—
Follow-up after TKI discontinuation in months, median [range]		13 [9–14]	9	13	14
Time to molecular relapse in months, median [range]		3 [3–4]	3	4	3
Time to recommencement of TKI therapy in months, median [range]		2 [1–2]	1	2	2
Time to MMR after molecular relapse in months, median [range]		1 [1–3]	1	1	3
Time to DMR after failed TFR in months, median [range]		4 [2–6]	2	4	6
Response at last follow-up, n (%)	MR4.0	1 (33)			X
	MR4.5	2 (67)	X	X

TKI: tyrosine kinase inhibitor; DMR: deep molecular response; MR4.5: ≥4.5-log reduction in BCR-ABL1 transcripts from baseline; MR4.0: ≥4.0-log reduction in BCR-ABL1 transcripts from baseline; MMR: major molecular response. Total TFR cohort = 12 patients.